OTC · ELOX
Healthcare · Biotechnology
$20.98
Up+$2.94 (+16.27%)
Updated Aug 23, 2026, 6:52 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ELOX closed at $20.98 after 20 trading sessions, up 73.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $19.00 | $23.3999 | $18.04 | $20.975 | 93.39K |
| Aug 20, 2026 | $19.00 | $19.18 | $17.75 | $18.04 | 40.28K |
| Aug 19, 2026 | $17.56 | $19.00 | $16.90 | $18.155 | 62.74K |
| Aug 18, 2026 | $18.47 | $18.47 | $16.50 | $18.25 | 38.25K |
| Aug 17, 2026 | $18.87 | $18.90 | $17.735 | $18.47 | 27.93K |
| Aug 14, 2026 | $19.23 | $19.23 | $17.17 | $18.76 | 29.64K |
| Aug 13, 2026 | $18.15 | $19.19 | $17.8035 | $19.07 | 33.28K |
| Aug 12, 2026 | $19.82 | $19.855 | $17.2538 | $18.265 | 45.15K |
| Aug 11, 2026 | $18.39 | $19.96 | $17.98 | $19.18 | 51.27K |
| Aug 10, 2026 | $16.80 | $18.48 | $16.80 | $17.00 | 62.61K |
| Aug 7, 2026 | $17.88 | $18.3799 | $17.39 | $17.57 | 32.43K |
| Aug 6, 2026 | $17.4145 | $18.5883 | $16.50 | $17.71 | 20.53K |
| Aug 5, 2026 | $18.03 | $19.30 | $16.5379 | $17.88 | 58.57K |
| Aug 4, 2026 | $18.44 | $19.10 | $17.5001 | $18.43 | 44.61K |
| Aug 3, 2026 | $18.24 | $19.358 | $15.67 | $18.45 | 65.89K |
| Jul 31, 2026 | $13.90 | $18.4212 | $13.79 | $17.43 | 53.37K |
| Jul 30, 2026 | $12.41 | $13.7499 | $12.41 | $13.30 | 18.88K |
| Jul 29, 2026 | $13.36 | $14.00 | $12.01 | $12.24 | 53.67K |
| Jul 28, 2026 | $12.01 | $13.50 | $11.81 | $12.81 | 22.36K |
| Jul 27, 2026 | $11.79 | $12.11 | $10.975 | $12.11 | 238.63K |
The latest Smart Investors Daily articles mentioning ELOX.
ELOX research
Company profile and research snapshot.
ELOXX PHARMACEUTICALS INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Jul 22, 2026 | LifeSci Capital | Outperform | — |
| Jul 20, 2026 | Guggenheim | Buy | — |
| Jul 11, 2023 | Oppenheimer | Outperform | — |
| Apr 6, 2023 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 21, 2026
Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million. Jupiter Neurosciences (NASDAQ:JUNS)
Benzinga · Aug 20, 2026
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $38.
Benzinga · Jul 22, 2026
LifeSci Capital analyst Rami Katkhuda initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $40.
Benzinga · Jul 20, 2026
Guggenheim analyst Vamil Divan initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $43.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ELOX.
